



AMENDMENTS TO THE CLAIMS


1. (Currently amended) A ~~compound~~ pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels or inhibiting cellular proliferation in a mammal, comprising having any one of the following formulas:




Genus 1;



Genus 2;



Genus 3; and



Genus 4;

Appl. No. : 10/821,667
Filed : April 9, 2004

wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₃, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, CN, CF₃, OCF₃, NO₂, COOR'', CHO, and COR'';

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur, and wherein R₁ and R₂ are not both methyl or phenyl;

wherein said substituents of the substituted alkyl, the substituted C₃-C₉ cycloalkyl, the substituted phenyl, the substituted naphthyl and the substituted heterocyclic are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, COOR' COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR' and CONR'R';

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and

wherein R'' is selected from the group consisting of C₁-C₉ alkyl, wherein said C₁-C₉ alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl.

2. (Currently amended) The compound pharmaceutical composition of Claim 1, wherein said polycyclic aliphatic group is selected from the group consisting of adamantyl, bicycloheptyl, camphoryl, bicyclo[2,2,2]octanyl, and norbornyl.

Appl. No. : 10/821,667
Filed : April 9, 2004

3. (Currently amended) The ~~compound~~ pharmaceutical composition of Claim 1, wherein said heterocyclic and said substituted heterocyclic is selected from the group consisting of pyridines, thiazoles, isothiazoles, oxazoles, pyrimidines, pyrazines, furans, thiophenes, isoxazoles, pyrroles, pyridazines, 1,2,3-triazines, 1,2,4-triazines, 1,3,5-triazines, pyrazoles, imidazoles, indoles, quinolines, iso-quinolines, benzothiophenes, benzofurans, parathiazines, pyrans, chromenes, pyrrolidines, pyrazolidines, imidazolidines, morpholines, thiomorpholines, and the corresponding saturated heterocyclics.

4. (Currently amended) The ~~compound~~ pharmaceutical composition of Claim 1, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction, and/or cell proliferation ~~and/or inhibition of cytokines or leukocytes~~.

5. (Withdrawn) A method for treating or preventing an allergic reaction and/or for inhibiting cytokines or leukocytes in a mammal wherein said reaction is caused by an increase in IgE levels comprising administering an IgE-suppressing amount of at least one compound of Claim 1.

6. (Withdrawn) The method of Claim 5 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said allergic reaction.

7. (Withdrawn) The method of Claim 6, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β_2 -adrenergic agonist, a long-acting β_2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

8. (Withdrawn) The method of Claim 6, wherein said at least one additional ingredient is combined with said at least one IgE-suppressing compound in a pharmaceutically acceptable diluent and co-administered to the mammal.

9. (Withdrawn) The method of Claim 8, wherein said at least one IgE-suppressing compound is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.

Appl. No. : 10/821,667
Filed : April 9, 2004

10. (Withdrawn) The method of Claim 9, wherein said dose is administered in divided doses at regular periodic intervals.

11. (Withdrawn) The method of Claim 10, wherein said regular periodic intervals occur daily.

12. (Withdrawn) A method for treating or preventing asthma in a mammal comprising administering an IgE-suppressing amount of at least one compound of Claim 1.

13. (Withdrawn) The method of Claim 12 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said asthma.

14. (Withdrawn) The method of Claim 13, wherein said additional ingredient is selected from the group consisting of a short-acting β_2 -adrenergic agonist, a long-acting β_2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

15. (Withdrawn) A method for inhibiting cellular proliferation in a mammal comprising administering an amount of at least one compound of Claim 1.

16. (Withdrawn) The method of Claim 15 further comprising administering at least one additional ingredient which is active in reducing at least one symptom associated with said cellular proliferation.

17. (Withdrawn) The method of Claim 16, wherein said at least one additional ingredient is selected from the group consisting of antifungals, antivirals, antibiotics, anti-inflammatories, and anticancer agents.

18. (Withdrawn) The method of Claim 16, wherein said at least one additional ingredient is selected from the group consisting of alkylating agent, antimetabolite, DNA cutter, topoisomerase I poison, topoisomerase II poison, DNA binder, and spindle poison.

19. (Withdrawn) The method of Claim 16, wherein said at least one additional ingredient is combined with said at least one compound of Claim 1 in a pharmaceutically acceptable diluent and co-administered to the mammal.

20. (Withdrawn) The method of Claim 19, wherein said at least one compound of Claim 1 is administered at a dose of about 0.01 mg to about 100 mg per kg body weight per day.

Appl. No. : 10/821,667
Filed : April 9, 2004

21. (Withdrawn) The method of Claim 20, wherein said dose is administered in divided doses at regular periodic intervals.


22. (Withdrawn) The method of Claim 21, wherein said regular periodic intervals occur daily.

23. (Withdrawn) The method of Claim 15 further comprising administering at least one other therapy which is effective in ameliorating at least one symptom associated with cellular hyperproliferation.


24. (Withdrawn) The method of Claim 23, wherein said therapy is an anti-cancer therapy.

25. (Withdrawn) The method of Claim 23, wherein said therapy is selected from the group consisting of radiation, immunotherapy, gene therapy, and surgery.

26. **(Currently amended)** The ~~compound~~ pharmaceutical composition of Claim 1, wherein R₁ and R₂ are independently selected from ~~Genera 1-4, preferred substituents for R₁ and R₂~~ are selected from the following:



27. (Withdrawn) A method of preparing a compound or salt thereof having the formula:



Genus 1;

wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₃, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, CN, CF₃, OCF₃, NO₂, COOR'', CHO, and COR'';

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, COOR' COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR' and CONR'R';

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and


wherein R'' is selected from the group consisting of C₁-C₉ alkyl, wherein said C₁-C₉ alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl;

wherein said method comprises steps:


converting a Y-substituted-nitro-benzonitrile to a Y-substituted nitro-benzamidine;

reacting the Y-substituted nitro-benzamidine with X-substituted nitro-phenacyl


halide to form a species of the formula 13 ;




reducing the species of the formula 13 to form a species of the formula 14



acylating the species of the formula 14 to form a species of the formula 15



28. (Withdrawn) A method of preparing a compound or salt thereof having the formula:



wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₃, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, CN, CF₃, OCF₃, NO₂, COOR'', CHO, and COR'';

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, COOR' COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR' and CONR'R';

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein


said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and

wherein R'' is selected from the group consisting of C₁-C₉ alkyl, wherein said C₁-C₉ alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl;

wherein said method comprises steps:


converting a Y-substituted nitro-benzonitrile to a Y-substituted nitro-benzamidine;

reacting the Y-substituted nitro-benzamidine with X-substituted acetamido-




phenacyl halide to form species of the formula **74** ;


hydrolyzing the species of the formula **74** to form a species of the formula




acylating the species of the formula **75** to form a species of the formula **76**




reducing the species of the formula **76** to form a species of the formula **77**



acylating the species of the formula **77** to form a species of the formula



29. (Withdrawn) A method of preparing a compound or salt thereof having the formula:



wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₃, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, CN, CF₃, OCF₃, NO₂, COOR'', CHO, and COR'';

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, COOR' COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR' and CONR'R';

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and


wherein R'' is selected from the group consisting of C₁-C₉ alkyl, wherein said C₁-C₉ alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl;

wherein said method comprises the following steps:


converting a Y-substituted-nitro-benzonitrile to a Y-substituted nitro-benzamidine;

reacting the Y-substituted nitro-benzamidine with X-substituted cyano-phenacyl

halide to form a species of the formula **92** ;




reducing the species of the formula **92** to form a species of the formula **93**




acylating the species of the formula **93** and subsequently performing a hydrolysis


to form a species of the formula **94** ; and



aminating the species of the formula **94** to form a species of the formula **95**



30. (Withdrawn) A method of preparing a compound or salt thereof having the formula:



wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₃, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, CN, CF₃, OCF₃, NO₂, COOR'', CHO, and COR'';

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, COOR' COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR' and CONR'R';

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and

wherein R'' is selected from the group consisting of C₁-C₉ alkyl, wherein said C₁-C₉ alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl;


wherein said method comprises the following steps:

Appl. No. : 10/821,667
Filed : April 9, 2004


converting a Y-substituted nitro-benzonitrile to a Y-substituted nitro-benzamidine;

converting methyl X-substituted 4-acetyl benzoate to a methyl X-substituted 4-(alpha-bromoacetyl) benzoate;


reacting the Y-substituted nitro-benzamidine with methyl X-substituted 4-(alpha-bromoacetyl) benzoate to form species of the formula 103



hydrolyzing the species of the formula 103 to form a species of the formula 104




aminating the species of the following formula 104 to form a species of the




formula 105 ; and

reducing and amidating the formula 105 to form a species of the formula 106



31. (Withdrawn) A method of preparing a compound or salt thereof having the formula:



Genus 3;

wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₃, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, CN, CF₃, OCF₃, NO₂, COOR'', CHO, and COR'';

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, COOR' COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR' and CONR'R';

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and


wherein R'' is selected from the group consisting of C₁-C₉ alkyl, wherein said C₁-C₉ alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl;

wherein said method comprises the following steps:


converting a Y-substituted-alkoxycarbonyl-benzonitrile to a Y-substituted alkoxycarbonyl-benzamidine;

reacting the Y-substituted alkoxycarbonyl-benzamidine with X-substituted cyano-


phenacyl halide to form a species of the formula **142** ;




hydrolyzing the species of the formula **142** to form a species of the formula **143**



amidating the species of the formula **143** to form a species of the formula **143a**




hydrolyzing the species of the formula **143a** to form a species of the formula **143b**




; and

amidating the species of the formula **143b** to form a species of the formula **144**



32. (Withdrawn) A method of preparing a compound or salt thereof having the formula:



Genus 4;

wherein R is selected from the group consisting of H, C₁-C₅ alkyl, benzyl, p-fluorobenzyl, and dialkylaminoalkyl, wherein said C₁-C₅ alkyl is selected from the group consisting of a straight chain, branched or cyclic alkyl;

wherein R₃, X, and Y are independently selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, CN, CF₃, OCF₃, NO₂, COOR'', CHO, and COR'';

wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heterocyclic, and substituted heterocyclic, wherein said heterocyclic and said substituted heterocyclic contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur;

wherein said substituents are selected from the group consisting of H, halogen, alkoxy, substituted alkoxy, alkyl, substituted alkyl, dialkylaminoalkyl, hydroxyalkyl, OH, OCH₃, COOH, COOR' COR', CN, CF₃, OCF₃, NO₂, NR'R', NHCOR' and CONR'R';

wherein R' is selected from the group consisting of H, alkyl, substituted alkyl, C₃-C₉ cycloalkyl, substituted C₃-C₉ cycloalkyl, polycyclic aliphatic groups, phenyl, substituted phenyl, naphthyl, substituted naphthyl, heteroaryl and substituted heteroaryl, wherein said heteroaryl and said substituted heteroaryl contain 1-3 heteroatoms, wherein said heteroatom is independently selected from the group consisting of nitrogen, oxygen and sulfur; and


wherein R'' is selected from the group consisting of C₁-C₉ alkyl, wherein said C₁-C₉ alkyl is selected from the group consisting of straight chain alkyl, branched alkyl, and cyclic alkyl;

wherein said method comprises the following steps:


converting a Y-substituted-alkoxycarbonyl-benzonitrile to a Y-substituted alkoxycarbonyl-benzamidine;

reacting the Y-substituted alkoxycarbonyl-benzamidine with X-substituted nitro-


phenacyl halide to form a species of the formula **152** ;



reducing the species of the formula **152** to form a species of the formula **153**




acylating the species of the formula **153** to form a species of the formula **154**



; and

amidating the species of the formula **154** to form a species of the formula **155**



33. (New) A compound selected from the group consisting of:

N-{4-[5-(4-cycloheptylamino-phenyl)-1H-imidazol-2-yl]-phenyl}-
 cycloheptylamide,

N-{4-[2-(4-(4-fluorobenzoylamino)-phenyl)-3H-imidazol-4-yl]-phenyl}-4-fluoro-
 benzamide,

N-{4-[5-(4-cyclohexylamino-phenyl)-1H-imidazol-2-yl]-phenyl}-
 cyclohexylamide,

N-{4-[2-(4-(2,4-dichlorobenzoylamino)-phenyl)-3H-imidazol-4-yl]-phenyl}-2,4-
 dichloro-benzamide,

N-{4-[5-(4-(2-methylcyclohexyl)-amino-phenyl)-1H-imidazol-2-yl]-phenyl}-(2-
 methylcyclohexyl)-amide,

Appl. No. : 10/821,667
Filed : April 9, 2004

N-(3-(5-(3-(1-Adamantanamido)phenyl)-1H-imidazol-2-yl)phenyl)-1-adamantanecarboxamide,
N-(4-(5-(3-(1-Adamantanamido)phenyl)-1H-imidazol-2-yl)phenyl)-1-adamantanecarboxamide,
N-{4-[5-(4-(2-methylcyclohexyl)-amino-phenyl)-1H-imidazol-2-yl]-phenyl}-(4-methylcyclohexyl)-amide,
N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)picolinamide,
N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)-4-methylcyclohexanecarboxamide,
N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)-2-methylcyclohexanecarboxamide,
N-(4-(5-(4-adamantylamidophenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,
N-(4-(2-(4-adamantylamidophenyl)-1H-imidazol-5-yl)phenyl)cyclohexanecarboxamide,
N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,
N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-2-methylcyclohexylamide,
N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptylamide,
4-chloro-N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)benzamide,
3,4-chloro-N-(4-(5-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)benzamide,
N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,
N-(4-(2-(4-adamantylamidophenyl)-1H-imidazol-5-yl)phenyl)-4-methylcyclohexanecarboxamide,

Appl. No. : 10/821,667
Filed : April 9, 2004

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)benzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-4-fluorobenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-4-chlorobenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-3,4-dichlorobenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-4-methoxybenzamide,

N-(4-(5-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)-2,3,4,5,6-pentafluorobenzamide,

N-(4-(2-(4-Adamantylamidophenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(Cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(4-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(5-(4-(Cycloheptanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)nicotinamide,

N-(4-(2-(4-(Benzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(2,3,4,5,6-Pentafluorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

N-(4-(2-(4-(3,4-Dichlorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,

Appl. No. : 10/821,667
Filed : April 9, 2004

N-(4-(2-(4-(4-Fluorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,
N-(4-(2-(4-(4-Chlorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,
N-(4-(2-(4-(4-Methoxybenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,
N-(4-(2-(4-(4-Nitrobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)cycloheptanecarboxamide,
N-(4-(2-(4-(1-Adamantanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,
N-(4-(2-(4-(Cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,
N-(4-(2-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,
N-(4-(2-(4-(4-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,
N-(4-(2-(4-(Nicotinamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,
N-(4-(2-(4-(3,4-Dichlorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,
N-(4-(2-(4-(2,3,4,5,6-Pentafluorobenzamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,
N-(4-(2-(4-(Cycloheptanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)nicotinamide,
2-Methyl-N-(4-(2-(4-(cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)phenyl)cyclohexanecarboxamide,
N-(4-(5-(4-(2-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)nicotinamide,
2-Methyl-N-(4-(2-(4-(4-methylcyclohexanamido)phenyl)-1H-imidazol-5-yl)phenyl)cyclohexanecarboxamide,

Appl. No. : 10/821,667
Filed : April 9, 2004

N-(4-(5-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,

N-(4-(5-(4-(2-Methylcyclohexanecarboxamido)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(5-(4-(pyridin-2-ylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,

N-(4-(5-(4-(pyridin-2-ylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)cyclohexanecarboxamide,

N-(4-(5-(4-(cycloheptylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)benzenamide,

N-(4-(5-(4-(cycloheptylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

N-(4-(5-(4-(cycloheptylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide,

4-(2-(4-(4-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)-N-cycloheptylbenzamide,

4-(2-(4-(2-methylcyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)-N-cycloheptylbenzamide,

4-(2-(4-adamantylamidophenyl)-1H-imidazol-5-yl)-N-cycloheptylbenzamide,

Adamantane-1-carboxylic acid (4-{5-[4-(adamantan-2-ylcarbamoyl)-phenyl]-1H-imidazol-2-yl}-phenyl)-amide,

N-Adamantan-2-yl-4-[2-[4-(cyclohexanecarbonyl-amino)-phenyl]-3H-imidazol-4-yl]-benzamide,

Cycloheptane carboxylic acid (4-{5-[4-(adamantan-2-ylcarbamoyl)-phenyl]-1H-imidazol-2-yl}-phenyl)-amide,

Pyridine-2-carboxylic acid (4-{5-[4-(adamantan-2-ylcarbamoyl)-phenyl]-1H-imidazol-2-yl}-phenyl)-amide,

N-(4-(5-(4-(Cyclohexylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)picolinamide,

Appl. No. : 10/821,667
Filed : April 9, 2004

N-(4-(2-(4-(Cyclohexanecarboxamido)phenyl)-1H-imidazol-5-yl)-N-cyclohexylbenzamide,

N-(4-(5-(4-(Cyclohexylcarbamoyl)phenyl)-1H-imidazol-2-yl)phenyl)cycloheptanecarboxamide.